Zoxamide

Zoxamide

SCHEMBL170285

CC[C@](C)(NC(=O)c1cc(Cl)c(C)c(Cl)c1)C(=O)CCl

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B13 Q7Z5P4 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
ANO1 Q5XXA6 3/20 0.34
HTT P42858 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zoxamide SCHEMBL70113 1.00 LMNA (0.36) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL7170744 1.00 LMNA (0.36) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL17701171 0.99 LMNA (0.35) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL17701155 0.95 DDR1 (0.33) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL14676134 0.95 GAA (0.35) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL17701169 0.90 KDM4E (0.32) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL21043613 0.89 KDM4E (0.32) LMNAPOLBGAAKDM4EALDH1A1
Zoxamide SCHEMBL7167110 0.89 POLB (0.39) LMNAPOLBGAAKDM4EALDH1A1
SCHEMBL7527475 0.87 HSD11B1 (0.38) LMNAGAAKDM4EALDH1A1HSD17B13
SCHEMBL7572038 0.87 HSD17B13 (0.36) LMNAPOLBGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9113630-B2 Method of controlling particular insect pests by applying anthranilamide compounds E I DU PONT DE NEMOURS AND COMPANY (US) 2015-08-25 US claimed
US-8921400-B2 Arthropodicidal anthranilamides E I DU PONT DE NEMOURS AND COMPANY (US) 2014-12-30 US claimed
US-20140141972-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT E I DU PONT NEMOURS AND COMPANY (US) 2014-05-22 US claimed
US-8637552-B2 Anthranilamide arthropodicide treatment E I DU PONT DE NEMOURS AND COMPANY (US) 2014-01-28 US claimed
US-20130031677-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT E I DU PONT DE NEMOURS AND COMPANY (US) 2013-01-31 US claimed
US-20120171183-A1 ARTHROPODICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-07-05 US claimed
US-20100152194-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-06-17 US claimed
US-7696232-B2 Anthranilamide arthropodicide treatment E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-04-13 US claimed
EP-1700845-B1 Insecticidal anthranilamides DU PONT (US) 2008-12-10 EP claimed
EP-1427285-B1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT DU PONT (US) 2007-08-22 EP claimed
EP-1700845-A1 Insecticidal anthranilamides E.I.Du pont de nemours and company (US) 2006-09-13 EP claimed
US-20040209923-A1 Anthranilamide arthropodicide treatment FMC CORPORATION 2004-10-21 US claimed
EP-1427285-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT E. I. du Pont de Nemours and Company (US) 2004-06-16 EP claimed
WO-2003024222-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2003-03-27 WO claimed
US-20260101901-A1 DELAYING BLOOM IN HORTICULTURAL CROPS USING JASMONIC ACID BIOSYNTHESIS INHIBITORS VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) 2026-04-16 US disclosed
US-12590341-B2 Brassica GAT event and compositions and methods for the identification and/or detection thereof PIONEER HI-BRED INTERNATIONAL, INC. (US) 2026-03-31 US disclosed
US-12221436-B2 Anthranilamides, their use as insecticide and processes for preparing the same PI INDUSTRIES LTD. (IN) 2025-02-11 US disclosed
EP-0816330-B1 Process for the preparation of N-acetonylbenzamides ROHM & HAAS (US) 2000-12-27 EP disclosed
WO-2000053585-A1 AMIDE AND ESTER FUNGICIDES AND ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2000-09-14 WO disclosed
EP-0816330-A1 N-acetonylbenzamide fungicides ROHM AND HAAS COMPANY (US) 1998-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12221436-B2 Anthranilamides, their use as insecticide and processes for preparing the same CYP1A2, ANTXR2, DDT LMNA 1607/4885POLB 2716/4885GAA 1835/4885
US-12590341-B2 Brassica GAT event and compositions and methods for the identification and/or detection thereof DNTT, NAA50, NAA15 LMNA 3503/4885POLB 53/4885GAA 1553/4885
US-20260101901-A1 DELAYING BLOOM IN HORTICULTURAL CROPS USING JASMONIC ACID BIOSYNTHESIS INHIBITORS FADS2, DDT, MYB LMNA 3530/4885POLB 3978/4885GAA 2706/4885
US-20130031677-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT ANTXR2, ARF5, NPR1 LMNA 3703/4885POLB 4372/4885GAA 1554/4885
US-20040209923-A1 Anthranilamide arthropodicide treatment ANTXR2, ARF5, NPM1 LMNA 3468/4885POLB 4432/4885GAA 1184/4885
US-20100152194-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT ANTXR2, ARF5, NPR1 LMNA 3703/4885POLB 4372/4885GAA 1554/4885
US-20120171183-A1 ARTHROPODICIDAL ANTHRANILAMIDES ANTXR2, CYB5R3, NIT2 LMNA 3711/4885POLB 2919/4885GAA 2681/4885
US-20140141972-A1 ANTHRANILAMIDE ARTHROPODICIDE TREATMENT ANTXR2, ARF5, NPR1 LMNA 3703/4885POLB 4372/4885GAA 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.